期刊文献+

基于层次分析法的药品定价和报销决策模型设计 被引量:3

Drug Pricing and Reimbursement Modeling Based on Analytic Hierarchy Process
原文传递
导出
摘要 目的:提高创新药物定价和报销决策的科学性和透明度。方法:以一个假想的抗抑郁新药为例,在层次分析法的基础上建立层次结构模型并计算优先权重,综合评估影响药品定价和报销决策的多种因素并获得综合评价结果。结果与结论:模型将定价和报销决策中的部分定性因素定量化,从而提供了可靠的决策依据。虽然层次分析法在实际应用中需要探讨更多的影响因素和方法学问题,但其在药品定价和报销领域的应用是现实和可行的。 OBJECTIVE: To make a more scientific and transparent decision in new drug pricing and reimbursement. METHODS: A hierarchy structure model was established based on analytic hierarchy process with an imagined antidepressant drug as an example; the priority weights were calculated, and the multiple factors influencing pricing and reimbursement decision were evaluated synthetically to derive the synthetic evaluation results. RESULTS & CONCLUSIONS: The model can quantify part of the qualitative factors and provide reliable bases for drug pricing and reimbursement; although there are many factors and methodology issues need to be discussed when analytic hierarchy process is applied in reality, the method is realistic and feasible in drug pricing and reimbursement.
出处 《中国药房》 CAS CSCD 北大核心 2007年第25期1921-1923,共3页 China Pharmacy
关键词 药品 定价 报销 决策 层次分析法 模型 Drug Pricing Reimbursement Decision Analytic hierarchy process Model
  • 相关文献

参考文献3

  • 1Silvia ME,Sebastian S,Thomas DS.European health care policies for controlling drug expenditure[J].Pharmacoeconomics,2003,21(2):89.
  • 2吴晶,李剑青,黄泰康.国际药品定价理论与实践对我国药品定价的启示[J].中国药房,2007,18(7):487-489. 被引量:9
  • 3Sketris IS,Metge CJ,Ross JL,et al.The use of the World Health Organization anatomical therapeutic chemical/defined daily dose methodology in Canada[J].Drug Information Journal,2004,38(1):15.

二级参考文献5

  • 1Redwood H.The Dynamics of Drug Pricing and Reimbursement in the European Community[M].Felixstowe:Oldwicks Press,1992:87~ 96.
  • 2Guhl A.Pricing and reimbursement systems in Europe[J].Health Econ Prev Care,2000,1(3):8.
  • 3Kremer M.Pharmaceuticals and the developing world[J].J Econo Perspect,2002,16(4):67.
  • 4Danzon P.Reference pricing:efficient insurance design or monopsony free riding?[J].Pharma Pricing Review,1998,3(7):127.
  • 5Danzon PM.The Economics of Parallel Trade[J].Pharmaco Economics,1998,13(3):293.

共引文献8

同被引文献20

  • 1陈永法,邵蓉.在实践中不断完善国家基本药物政策[J].中国药业,2005,14(3):2-3. 被引量:17
  • 2樊天觉.角膜异物剔除术后使用贝复舒滴眼液的疗效观察[J].临床眼科杂志,2006,14(3):252-253. 被引量:6
  • 3World Health Organization. The selection and use of essential medicines:report of the WHO Expert Committee (including the 14th model list of essential medicines[J]. Geneva ,World Health Organization, 2006.
  • 4Polk EE,Wexler SA,Kymes S.Incidence of corneal epithelial defects with the standard and zero-compression hansatome microkeratomes[J].J Refract Surg,2005,21 (4):359-364.
  • 5Pastor JC,Calonge M.Epidermal growth factor and corneal wound healing.A multicenter study[J].Cornea,1992,11 (4):311-314.
  • 6Patented Medicine Prices Review Board.Budget Impact Analysis Guiedlines[J].Canada,2007.
  • 7Kataria MS, Bhaskarrao D. A clinical double-blind trial with a broad spectrum digestive enzyme product (Combi- zym) in geriatric practice[J]. Br J Clin Pract, 1969, 23 (1):15.
  • 8Wakasugi H.Experience using a digestive enzyme procduct (Combizym)-attempt to evaluate success by ty PFD test [J]. Rhinso to Kenkyu, 1982,59(9) : 163.
  • 9Marshall DA, Douglas PR, Drummond MF, et al. Budget impact analysis guidelines: guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada[J]. Pharmacoeconomics, 2008,26(6) :477.
  • 10孟锐,李颖.国家基本药物遴选与药物经济学[J].中国药房,2007,18(35):2721-2723. 被引量:27

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部